For the latest updates on our ongoing response to COVID-19, please click here.

Press Releases

Gilead Sciences and Second Genome Announce Strategic Collaboration in Biomarker and Inflammatory Bowel Disease Drug Discovery

-- Multi-year, Multi-program Agreement Leverages Latest Insights of Microbiome --

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and Second Genome, a leader in microbiome science, today announced that the companies have entered into a four-year strategic collaboration to identify biomarkers associated with clinical response in up to five of Gilead’s pipeline compounds in inflammation, fibrosis and other diseases, and to identify potential new targets and drug candidates for the treatment of inflammatory bowel disease (IBD).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200406005220/en/

Under the terms of the agreement, Second Genome will utilize its proprietary Microbiome Analytics Platform™ to identify novel biomarkers associated with clinical response to Gilead’s investigational medicines. This work will harness the latest insights in microbiome science to help inform patient stratification and optimize potential treatments for patients in the future. The platform, in combination with additional discovery and development tools, will also seek to identify new targets and drug candidates relevant to IBD. This will include the identification of up to five novel IBD targets or drug candidates over the next four years, with an option to extend the collaboration for an additional two years.

“There is a growing body of evidence that the microbiome plays an important role in disease progression and treatment response in inflammatory diseases,” said William Lee, PhD, Executive Vice President of Research at Gilead Sciences. “We look forward to working with Second Genome to investigate the microbiome’s role in inflammatory disease and particularly IBD, where patients can face significant challenges in achieving long-term remission with conventional therapies. This collaboration is the latest example of Gilead’s ongoing commitment to advance research in inflammatory diseases, combining external innovation and insights from Second Genome with our own expertise, as we work to bring forward transformative therapies to improve patient outcomes.”

“The Second Genome platform seeks to redefine diseases through the lens of the microbiome, utilizing this incredible resource to identify potential biomarkers and therapeutics,” said Karim Dabbagh, PhD, CEO of Second Genome. “We believe the microbiome holds insight into patient heterogeneity as well as response to specific therapies. These differences enable the identification of important biomarkers to enhance precision medicine for better patient segmentation as well as potential combination therapies. We are excited to be collaborating with Gilead using these approaches in IBD for new biomarkers as well as target and drug candidate discovery, driving toward improved clinical outcomes for patients.”

Second Genome will receive $38 million in an upfront payment, and up to approximately $300 million in success-based preclinical, clinical, regulatory and commercial milestones for each of five target discovery programs as well as low double-digit royalties for any approved products. In addition, it will receive success-based milestones for each validated biomarker delivered under the agreement.

Gilead will have the option to worldwide rights for up to five programs for all diseases as well as exclusive rights to all biomarkers developed under the collaboration.

About Second Genome

Second Genome identifies biomarkers, biological pathways, targets and potential therapeutics resulting from its knowledge and analysis of the human microbiome. We use our comprehensive microbiome-based drug discovery engine to discover and develop both microbially-derived protein therapeutics and biological targets resulting from how the microbiome influences a wide variety of diseases including cancer, gastrointestinal disorders as well as other inflammatory and metabolic diseases. Our pipeline includes preclinical programs in IBD and cancer, with our lead program SG-2-0776 in IBD expected to enter clinical development in 2021. For more information, please visit www.secondgenome.com.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead Forward Looking Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Gilead Sciences Contacts:
Douglas Maffei, PhD, Investors
(650) 522-2739

Arran Attridge, Media
(650) 425-8975
arran.attridge@gilead.com

Second Genome Media Contact:
Angela Bitting
Bitting Communications LLC
(925) 202-6211
a.bitting@comcast.net

Source: Gilead Sciences Inc.